LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
387
via benzinga.comMarkets

Capricor stock in focus ahead of FDA decision on deramiocel

FROM THE WIRE · BENZINGA.COM

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are in the spotlight Wednesday as investors position ahead of the FDA's decision on deramiocel, the company's cell therapy for Duchenne muscular dystrophy, set for Nov. 22.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe FDA decision due November 22 could move the shares of this small biotech sharply.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Capricor shares are in focus Wednesday ahead of the FDA decision.
  2. 02The decision concerns deramiocel, a cell therapy for Duchenne muscular dystrophy.
  3. 03The decision is scheduled for November 22.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.